BioSpace News Archive

BD, a leading global medical technology company, announced that David F. Melcher will be non-executive chair of the board of directors, and Claire Pomeroy, MD, MBA, will be a director of the company formed in connection with the previously announced separation of the Diabetes Care business into an independent, publicly traded company.

Draupnir Bio, a biotechnology company developing small molecule modulators of PCSK9 to transform the treatment of heart disease, announces the appointment of Anna Quattropani, PhD, as Chief Discovery Officer, effective immediately.

George Medicines, a late-stage drug development company focused on providing innovative and accessible medicines for the world’s leading causes of death, announces the appointment of Dr Charmaine Gittleson to the Board as Independent Non-Executive Director.

Merck, known as MSD outside the United States and Canada, announced the presentation of data from the company’s HIV clinical development program at the 11th International AIDS Society Conference on HIV Science from July 18-21.

FibroGen, Inc. announced the appointment of John Hunter, Ph.D., to the position of Chief Scientific Officer, where he will lead FibroGen’s research efforts, leveraging more than 20 years of global biopharmaceutical leadership and experience.

Lyra Therapeutics, Inc., a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat passages and other diseased tissues, announced that Maria Palasis, Ph.D., Lyra’s President and Chief Executive Officer, will present at the William Blair Biotech Focus Conference on Thursday, July 15, 2021 at 10:00 a.m. ET.

– Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, announced that the FDA has accepted a Pre-IND request for a potential cure of hepatitis B virus infection.

Making its first steps in West Africa, Nanox partners with EiLEENO Pharma to make medical imaging accessible and available across Nigeria to both public and private medical institutions

Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, announced the appointment of Jennifer Wellman to its board of directors.

Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announced today that the Central Ethics Committee has approved the proposed protocol modifications allowing additional immediate release oral opioids to be used as comparators in the REBORN1© study.